|
Name |
Dianhydroaurasperone C
|
Molecular Formula | C31H24O10 | |
IUPAC Name* |
4,5-dihydroxy-7-(5-hydroxy-6,8-dimethoxy-2-methyl-4-oxobenzo[g]chromen-10-yl)-6-methoxy-2-methylbenzo[g]chromen-8-one
|
|
SMILES |
CC1=CC(=C2C(=CC3=CC(=O)C(=C(C3=C2O)OC)C4=C5C(=C(C6=C4C=C(C=C6OC)OC)O)C(=O)C=C(O5)C)O1)O
|
|
InChI |
InChI=1S/C31H24O10/c1-12-6-17(32)25-21(40-12)9-14-8-19(34)26(30(39-5)22(14)28(25)35)24-16-10-15(37-3)11-20(38-4)23(16)29(36)27-18(33)7-13(2)41-31(24)27/h6-11,32,35-36H,1-5H3
|
|
InChIKey |
JYRJNZCKAAGZGP-UHFFFAOYSA-N
|
|
Synonyms |
Dianhydroaurasperone C; 92280-05-2; 4,5-dihydroxy-7-(5-hydroxy-6,8-dimethoxy-2-methyl-4-oxobenzo[g]chromen-10-yl)-6-methoxy-2-methylbenzo[g]chromen-8-one; Dianhydro-aurasperone C; CHEMBL4849390; DTXSID10238953; (7,10-Bi-4H-naphtho(2,3-b)pyran)-4,4'-dione, 5,5',8-trihydroxy-6,6',8'-trimethoxy-2,2'-dimethyl-
|
|
CAS | 92280-05-2 | |
PubChem CID | 146357 | |
ChEMBL ID | CHEMBL4849390 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 556.5 | ALogp: | 3.7 |
HBD: | 3 | HBA: | 10 |
Rotatable Bonds: | 4 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 141.0 | Aromatic Rings: | 6 |
Heavy Atoms: | 41 | QED Weighted: | 0.228 |
Caco-2 Permeability: | -5.172 | MDCK Permeability: | 0.00001660 |
Pgp-inhibitor: | 0.893 | Pgp-substrate: | 0.111 |
Human Intestinal Absorption (HIA): | 0.702 | 20% Bioavailability (F20%): | 0.001 |
30% Bioavailability (F30%): | 0.931 |
Blood-Brain-Barrier Penetration (BBB): | 0.001 | Plasma Protein Binding (PPB): | 70.72% |
Volume Distribution (VD): | 0.458 | Fu: | 46.22% |
CYP1A2-inhibitor: | 0.322 | CYP1A2-substrate: | 0.981 |
CYP2C19-inhibitor: | 0.389 | CYP2C19-substrate: | 0.151 |
CYP2C9-inhibitor: | 0.766 | CYP2C9-substrate: | 0.905 |
CYP2D6-inhibitor: | 0.01 | CYP2D6-substrate: | 0.821 |
CYP3A4-inhibitor: | 0.068 | CYP3A4-substrate: | 0.146 |
Clearance (CL): | 2.619 | Half-life (T1/2): | 0.137 |
hERG Blockers: | 0.004 | Human Hepatotoxicity (H-HT): | 0.169 |
Drug-inuced Liver Injury (DILI): | 0.982 | AMES Toxicity: | 0.138 |
Rat Oral Acute Toxicity: | 0.091 | Maximum Recommended Daily Dose: | 0.926 |
Skin Sensitization: | 0.263 | Carcinogencity: | 0.018 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.661 |
Respiratory Toxicity: | 0.061 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC003507 | 0.932 | D06GCK | 0.368 | ||||
ENC001411 | 0.868 | D0G4KG | 0.297 | ||||
ENC000922 | 0.868 | D04AIT | 0.267 | ||||
ENC001501 | 0.832 | D06NSS | 0.246 | ||||
ENC002093 | 0.775 | D03RTK | 0.245 | ||||
ENC002002 | 0.762 | D09DHY | 0.245 | ||||
ENC003154 | 0.748 | D02LZB | 0.245 | ||||
ENC003508 | 0.727 | D0K8KX | 0.245 | ||||
ENC005776 | 0.727 | D0FX2Q | 0.242 | ||||
ENC002884 | 0.689 | D0FA2O | 0.240 |